Business Description
Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the Saliva Glucose Biosensor, an organic thin-film transistor designed to precisely measure glucose levels in saliva for effective diabetes management. Beyond this, the company is actively developing a SARS-CoV-2 Biosensor, intended to serve as a supplementary diagnostic tool to existing RNA virus detection methods. It also maintains a broad biosensor platform that encompasses diverse diagnostic modalities, including biochemistry, immunology, tumor marker identification, hormone analysis, and nucleic acid diagnostics. Incorporated in 2016 and based in New York, New York, the company was formerly known as GBS Inc. before adopting its current name in October 2022. Intelligent Bio Solutions Inc. operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Business History
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -20.00
Total Equity: $3.00M
Shares: 527,364
Total Debt: $197,146
Cash: $1.02M
EBITDA: -$9.45M
Total Debt: $197,146
Cash: $1.02M
Revenue: $3.05M
Shares: 527,364
Revenue: $3.05M
Revenue: $3.05M
Revenue: $3.05M
Total Equity: $3.00M
Tax Rate: 0.0%
Equity: $3.00M
Total Debt: $197,146
Cash: $1.02M
Current Liabilities: $5.35M
Long-Term Debt: $0.00
Total Debt: $197,146
Total Equity: $3.00M
Shares: 527,364
Shares: 527,364
CapEx: -$231,838
Shares: 527,364
Stock Price: $2.25
Net Income: -$10.57M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 23, 2026 5:26pm (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $2.0M | $0 | $1.3M | $3.1M | $3.1M |
| Cost of Revenue | $0 | $0 | $930,204 | $1.7M | $1.8M |
| Gross Profit | $2.0M | $0 | $326,668 | $1.4M | $1.2M |
| Operating Expenses | $7.6M | $8.3M | $12.9M | $11.7M | $11.9M |
| Operating Income | -$5.6M | -$8.3M | -$12.6M | -$10.3M | -$10.6M |
| Net Income | -$7.0M | -$8.3M | -$10.6M | -$10.2M | -$10.6M |
| EBITDA | $0 | -$8.3M | -$9.5M | -$9.0M | -$9.5M |
| EPS | $-162.20 | $-113.30 | $-105.80 | $-63.80 | $-20.00 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 23, 2026 5:26pm (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $12.6M | $8.2M | $1.5M | $6.3M | $1.0M |
| Total Current Assets | $18.2M | $10.9M | $3.9M | $8.5M | $4.1M |
| Total Assets | $21.9M | $12.4M | $10.4M | $13.8M | $8.2M |
| Current Liabilities | $3.7M | $4.7M | $5.9M | $5.5M | $5.4M |
| Long-Term Debt | $0 | $0 | $759,027 | $0 | $0 |
| Total Liabilities | $6.9M | $5.8M | $6.7M | $5.6M | $5.4M |
| Total Equity | $15.1M | $6.6M | $3.8M | $8.3M | $3.0M |
| Retained Earnings | -$22.9M | -$31.2M | -$41.8M | -$52.0M | -$62.5M |
Cash Flow (Annual)
Last updated: Jun 23, 2026 5:26pm (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$11.3M | -$3.4M | -$7.4M | -$9.6M | -$9.7M |
| Capital Expenditure | $-3 | $-380,221 | $-505,123 | $-221,426 | $-231,838 |
| Free Cash Flow | -$11.3M | -$3.7M | -$7.9M | -$9.8M | -$9.9M |
| Acquisitions (net) | $0 | $0 | $-189,019 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $12.1M | -$4.3M | -$6.7M | $4.8M | -$5.3M |
Analyst Estimates (Annual)
Last updated: Jun 26, 2026 7:17pm (13h ago)| Metric | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| Revenue |
$4.2M $4.2M – $4.2M
|
$11.6M $11.6M – $11.6M
|
$26.3M $26.3M – $26.3M
|
$14.7M $14.7M – $14.7M
|
| EBITDA |
-$1.7M -$1.7M – -$1.7M
|
-$4.6M -$4.6M – -$4.6M
|
-$10.5M -$10.5M – -$10.5M
|
-$5.9M -$5.9M – -$5.9M
|
| Net Income |
-$19.4M -$19.4M – -$19.4M
|
-$6.6M -$6.6M – -$6.6M
|
$1.8M $1.8M – $1.8M
|
-$49.4M -$49.4M – -$49.4M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 23, 2026 5:26pm (3d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -100.0% | — | +147.6% | -1.9% |
| Gross Profit Growth | -100.0% | — | +336.4% | -12.5% |
| Operating Income Growth | -49.6% | -51.1% | +18.4% | -3.5% |
| Net Income Growth | -18.0% | -28.0% | +4.5% | -4.1% |
| EBITDA Growth | — | -13.8% | +4.5% | -4.5% |
Narrative Economics
market-narrative step).